Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study

Title: P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study
Authors: Mocci, G; Maconi, G; Onidi, F M; Cataletti, G; Elisei, W; Scaldaferri, F; Lorenzetti, R; Pagnini, C; Scarcelli, A; Graziani, M G; Di Paolo, M C; Pranzo, G; Luppino, I; Monterubbianesi, R; Faggiani, R; Ferronato, A; Savarino, E; Pica, R; Cocco, A; Rodino, S; Sebkova, L; Zampaletta, C; Gaiani, F; Fanigliulo, L; Allegretta, L; Cuomo, A; Donnarumma, L; Della Valle, N; Forti, G; Antonelli, E; Bassotti, G; Iannelli, C; Aragona, G; Lauria, A; Piergallini, S; Colucci, R; Binaghi, L; Meucci, C; Papa, A; Tursi, A
Source: Journal of Crohn's and Colitis ; volume 17, issue Supplement_1, page i635-i636 ; ISSN 1873-9946 1876-4479
Publisher Information: Oxford University Press (OUP)
Publication Year: 2023
Description: Background Current data about long-term use of vedolizumab (VDZ) in ulcerative colitis (UC) versus Crohn’s disease (CD) patients are limited. We aimed to assess whether there are differences in term of long-term efficacy and safety of VDZ in UC vs. CD patients. Methods Clinical activity was scored according to the Mayo score in UC and to the Harvey-Bradshaw Index (HBI) in CD. The primary endpoints were the achievement of clinical remission within 6 month of treatment, maintenance of clinical remission during a long follow-up, and safety. Secondary endpoints were clinical response to treatment, achievement of mucosal healing (MH), steroid discontinuation, and treatment optimization during the follow-up. Results The study group consisted of 729 patients (475 patients with UC and 254 CD patients with CD) with a median follow-up of 18 (interquartile range 6-36) months. Clinical remission at the 6th month of treatment was achieved in 488 (66.9%) patients, higher in CD patients (74.4 vs. 62.9, p
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/ecco-jcc/jjac190.0635
Availability: https://doi.org/10.1093/ecco-jcc/jjac190.0635; https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i635/51511471/jjac190.0635.pdf
Rights: https://academic.oup.com/pages/standard-publication-reuse-rights
Accession Number: edsbas.B31121A
Database: BASE